Fields marked as * are required.

 
 

Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion 
login

 70 Diseases   80 Investigators   51 Trials   26 News 
Show Filter Advanced
51 Trials

Remove Filter

 
TitleNRegionInterventionsSponsorStatusConditionsEndPhData-201420152016+
Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
75
Europe
cyclophosphamide, Vincristine, Prednisone, Rituximab, Powder and solvent for solution for infusion, Intravenous infusion, Buccal tablet, Myocet
(GOTEL) Grupo Oncológico para el tratamiento y estudio de los linfomas
Ongoing
Dose-dense modified R-CHOP regimen (R-COMP) in patients with aggressive NHL.
 
4
      
80
Europe
Powder and solvent for solution for infusion, MYOCET INFUS 2SET 50MG
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Completed
First line treatment on female breast cancer
 
3
      
363
US, Canada, Europe
Myocet
Sopherion Therapeutics
Active, not recruiting
Breast Cancer
03/09
3
      
Diamond
420
Europe
paclitaxel, Solution for infusion, Intravenous infusion, Tablet, Avastin, Paclitaxel Fresenius Kabi, Myocet, Xeloda
BOOG Study Center
Ongoing
Female patients with HER2/neu negative, incurable, metastatic or unresectable locally advanced breast cancer, who are candidates for chemotherapy.
 
3
      
420
Europe
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine, Non-pegylated liposomal doxorubicin (Myocet®), Non-pegylated liposomal doxorubicin (Myocet®):
Borstkanker Onderzoek Groep, Roche Pharma AG, Teva Pharma
Recruiting
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer
10/13
3
      
595
Europe
Carboplatin, Background therapy with, Paclitaxel, Myocet, Herceptin (Her2pos), Tyverb (Her 2 pos), Avastin (triple neg), background treatment according to standards fpr triple negative and Her2pos breast cancer patients
German Breast Group, TEVA, Roche Pharma AG, GlaxoSmithKline
Completed
Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, Tubular Breast Cancer Stage III, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer Stage IV, Inflammatory Breast Cancer
05/13
2/3
      
Diamond
Diamond
Diamond
25
Europe
MYOCET, DEXAMETHASONE, Lyophilisate and solvent for suspension for injection, Solution for injection, MYOCET 50mg, DEXAMETHASONE
CHRU de Brest, Cephalon, CHRU de Brest
Ongoing
Patient présentant un lymphome cérébral à cellules B réfractaire ou en rechute dans les 12 mois suivant une première ligne de chimiothérapie, lymphomes cérébraux à grandes cellules B réfractaire ou en rechute, Diseases [C] - Cancer [C04]
 
2
      
60
Europe
Solution for infusion, Powder for infusion*, Powder and solvent for solution for infusion, Tablet, MABTHERA EV 1FL 50ML 500MG, ENDOXAN BAXTER EV 1FL 500MG, VINCRISTINA PHARMACIA U. 2MG, MYOCET INFUS 2SET 50MG, DELTACORTENE FORTE 10CPR 25MG
G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
Completed
Treatment of patients with newly diagnosed splenic marginal non Hodgkin lymphoma
 
2
      
74
Europe
Taxotere®, Myocet ®, Concentrate for solution for infusion, Powder and solvent for solution for infusion, Taxotere®, Myocet®
Grupo Oncopaz y Hospitales Asociados
Ongoing
Advanced Breast cancer
 
2
      
75
Europe
Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)
Zeneus Pharma
Active, not recruiting
Aggressive Non-Hodgkin's Lymphoma in the Elderly.
10/05
2
      
45
Europe
Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab
Zeneus Pharma
Recruiting
Metastatic Breast Cancer
11/05
2
      
30
Europe
Powder and solvent for suspension for injection, Tablet, MYOCET IV 2 SET/3 FLAC.50 MG, XELODA 60 CPR RIV. 150MG
AZIENDA USL DI FORLI
Completed
Metastatic breast cancer pretreated
 
2
      
36
Europe
DOXORUBICINA, Powder and solvent for solution for infusion, MYOCET INFUS 2SET 50MG
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Completed
second line treatment in platinum resistant ovarian and endometrial cancer
 
2
      
41
Europe
Powder and solvent for suspension for injection, Solution for infusion, MYOCET IV 2 SET/3 FLAC.50 MG, TAXOTERE FL 20 MG/0,5ML F
AZIENDA USL 6 LIVORNO ZONA LIVORNESE
Ongoing
Patiens with metastatic breast cancer
 
2
      
69
Europe
Powder and solvent for solution for infusion, MYOCET
AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
Completed
Elderly patients with B non-Hodgkin lymphoma
 
2
      
100
Europe
Powder for solution for infusion, Intravenous infusion, Myocet, Adriablastin, Holoxan
Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
Ongoing
Patients with locally advanced or metastatic soft tissue carcinoma and without any prior treatment are eligible for this study.
 
2
      
35
Europe
Thalidomide, Powder for infusion*, Tablet, Oral drops, solution, MYOCET*INFUS 2SET 50MG, SOLDESAM*OS GTT 10ML 0,2%
ISTITUTO EUROPEO DI ONCOLOGIA
Ongoing
Multiple Myeloma
 
2
      
39
Europe
Myocet, Carboplatin, TLC D_99, Carboplatin, Concentrate for solution for infusion, Injection, Myocet, Carboplatin "EBEWE"
Studienzentrale AGO Austria
Ongoing
primary advanced or recurrent/metastatic endometrial cancer
 
2
      
120
Europe
MYOCET®, Rituximab, Cyclophosphamide, Vincristine, Prednisone, NEUPOGEN®, NEULASTA®, NeoRecormon®, Powder and solvent for solution for infusion, Solution for infusion, Powder for solution for infusion, Tablet, Solution for injection, Powder and solvent for solution for injection, MYOCET®, NEUPOGEN®, NEULASTA®, NeoRecormon®
Institut Bergonié
Ongoing
Vulnerable/Frail elderly patients older than 70 with diffuse large B-cell lymphoma stage II, III, or IV
 
2
      
32
Europe
Emulsion for infusion, MYOCET, HOLOXAN*EV 1FL 1G
CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
Ongoing
METASTATIC SOFT TISSUE SARCOMAS
 
2
      
30
Europe
Concentrate for solution for infusion, MYOCET
UNIVERSITA, CAMPUS BIOMEDICO
Ongoing
epithelial ovarian carcinoma recidivist
 
2
      
17
Europe
Powder for solution for injection, MYOCET
ISTITUTO NAZIONALE PER LA CURA TUMORI
Ongoing
recurrence of high grade glioblastoma
 
2
      
69
Europe
trastuzumab [Herceptin], Herceptin, paclitaxel, Myocet
Hoffmann-La Roche
Completed
Breast Cancer
09/09
2
      
110
Europe
Powder and solvent for solution for infusion, Film-coated tablet, MYOCET, XELODA
AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
Ongoing
Population of female patients suffering from breast cancer in initial clinical stage IIIA, IIIB and IIIC not expressing HER2 and who have not obtained a pathological complete response (defined
 
2
      
70
Europe
Non pegylated liposomal doxorubicin and docetaxel, Myocet, Taxotere
Catharina Ziekenhuis Eindhoven, Cephalon, Sanofi
Completed
Breast Cancer, Neoplasm Metastasis
11/09
2
      
44
Europe
RCOMP-14 + rituximab
Asociacion Doctor Peset Para el Estudio de la Hematología, Cephalon, Pivotal S.L.
Recruiting
No Hodgkin B Lymphoma
11/09
2
      
39
Europe
carboplatin, liposome-encapsulated doxorubicin citrate, laboratory biomarker analysis, quality-of-life assessment
Medical University Innsbruck
Recruiting
Endometrial Cancer
10/10
2
      
24
Europe
trastuzumab-MCC-DM1 (TDM-1), RO5304020/F02, Powder and solvent for solution for infusion, Powder for solution for infusion, Solution for injection, Powder for solution for injection, Concentrate for solution for infusion, TAXOTERE 20 mg/1 ml concentrado para solución para perfusión, MYOCET 50 mg polvo y premezclas concentrado para dispersión liposómica para perfusión, EPIRUBICINA MAYNE 2 mg/ml solución inyectable, FLUOROURACILO FERRER FARMA 50 mg/ml solución inyectable, GENOXAL 1 g Inyectable, TAXOTERE 80 mg/4 ml concentrado para solución para perfusión, HERCEPTIN 150 mg polvo para concentrado para solución para perfusión
F. Hoffmann-La Roche Ltd
Ongoing
Neoadyuvante o adyuvante en cáncer de mamaTreatment of HER2 positive adjuvant or neoadjuvant therapy
 
2
      
83
Europe
Docetaxel, Liposomal doxorubicine and Cyclophosphamide
Grupo Oncológico Gallego, Pivotal S.L.
Active, not recruiting
Breast Cancer
01/11
2
      
50
Europe
Rituximab, Cyclophosphamide, Vincristine, Prednisone, Doxorubicin
Fondazione Italiana Linfomi ONLUS
Recruiting
Diffuse Large B-Cell Lymphoma
05/11
2
      
Diamond
6
Europe
liposomal Doxorubicin, Myocet
University of Magdeburg
Recruiting
Metastatic Breast Cancer
12/11
2
      
154
Europe
Myocet, Gemzar 200mg, Gemzar 1g, TLC D_99, Concentrate for solution for infusion, Powder for solution for infusion, Myocet, Gemzar 200mg, Gemzar 1g
Studienzentrale AGO Austria
Terminated
platinum-refractory and platinum-resistant epithelial cancer of the ovary, fallopian tube, and the peritoneum
12/11
2
      
94
Europe
Rituximab, MabThera, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, liposomal Doxorubicin, Myocet, Vincristin, Oncovin, Prednisolone
Arbeitsgemeinschaft medikamentoese Tumortherapie
Completed
Diffuse Large B-Cell Lymphoma
01/12
2
      
60
Europe
Non pegylated liposomal doxorubicin, trastuzumab, docetaxel, Myocet, herceptin, toxotere
Catharina Ziekenhuis Eindhoven, Cephalon, Sanofi
Recruiting
Breast Cancer, Neoplasm Metastasis
07/12
2
      
44
Europe
Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet
Hospital Universitario Madrid Sanchinarro
Recruiting
Breast Cancer
02/13
2
      
Diamond
Diamond
Diamond
26
US
filgrastim, pegylated liposomal doxorubicin hydrochloride
Brown University
Active, not recruiting
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
12/13
2
      
46
Europe
Cyclophosphamide, Endoxan, Liposomal-encapsulated doxorubicin, Myocet
Hellenic Oncology Research Group
Recruiting
Breast Cancer
03/14
2
      
112
Europe
Metformin + Myocet + Cyclophosphamide, Myocet + Cyclophosphamide
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Recruiting
HER2-negative Metastatic Breast Cancer Patients
04/14
2
      
154
Europe
gemcitabine hydrochloride, liposome-encapsulated doxorubicin citrate, quality-of-life assessment
Medical University Innsbruck
Recruiting
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
05/14
2
      
126
Europe
MYOCET® Plus Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles, Free Doxorubicin Plus Cyclophosphamide, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles
Cephalon
Active, not recruiting
Breast Cancer
10/15
2
     
Hourglass
25
Europe
infusion of MYOCET
University Hospital, Brest
Recruiting
Cerebral Lymphoma B Cell Refractory
10/15
2
     
90
Europe
RCOMP, Rituximab, Myocet, Cyclophosphamide, Vincristine, Prednisone, RCHOP, Doxorubicin, Prednisone 60 mg/m2
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Recruiting
Lymphoma
11/15
2
     
83
Europe
Liposomal Doxorubicin, Myocet® (liposome-encapsulated doxorubicin)
SOLTI Breast Cancer Research Group
Active, not recruiting
Breast Cancer
07/16
2
    
US
trastuzumab, pegylated liposomal doxorubicin hydrochloride
Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Completed
Breast Cancer
08/03
1/2
      
59
Europe
Myocet, Taxotere, Herceptin
Spanish Breast Cancer Research Group, Zeneus Pharma, Sanofi, Hoffmann-La Roche, Amgen
Completed
Breast Cancer
12/07
1/2
      
36
Europe
combination of TLC D-99 and Ifosfamide
Istituto Clinico Humanitas
Completed
Sarcoma, Soft Tissue
12/09
1/2
      
100
Europe
Lapatinib, Tyverb
Sana-Klinikum Lichtenberg
Recruiting
Breast Cancer
09/11
1/2
      
Diamond
Diamond
21
Europe
non-pegylated liposomal doxorubicon (Myocet™), Lapatinib (Tyverb™)
ICORG- All Ireland Cooperative Oncology Research Group
Recruiting
Her2 Positive Metastatic Breast Cancer
05/14
1/2
      
88
Europe
carboplatin and liposomal doxorubicin, carboplatin, liposomal doxorubicin, Myocet
ARCAGY/ GINECO GROUP
Recruiting
Ovarian Cancer
12/14
1/2
     
310
Europe
Myocet, Cisplatin, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Myocet
Klinikum der Universität München Innenstadt, I. Frauenklinik
Ongoing
This is an open-label, multicenter, randomized controlled, Phase I/II study comparing the time to progressive disease after randomisation in patients treated with 6 cycles of liposomal-encapsulated Doxorubicin (Myocet®) and Cisplatin chemotherapy versus liposomal-encapsulated Doxorubicin and Cisplatin chemotherapy combined with locoregional hyperthermia.
 
1
      
25
Europe
Carboplatino, 65108, Concentrate for dispersion for infusion, Concentrate and solvent for solution for infusion, MYOCET 50 MG POLVO Y PREMEZCLAS CONCENTRADO PARA DISPERSION LIPOSOMICA PARA PERFUSION, CARBOPLATINO TEVA 10 mg/ml CONCENTRADO PARA SOLUCION PARA PERFUSION
Dr. Andrés Poveda Velasco, Lavoratorios TEVA
Ongoing
gynecological cancer cancer ginecológico, gynecological cancer cancer ginecológico, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
1
      

Download Options
Help
Data releaseClick for data release
Data release (new)Click for data release (new)
Results pendingResults pending
Milestone resultClick for milestone result
Milestone result (new)Click for milestone result (new)
Milestone detailsClick for milestone details
MilestonesDisplay milestones
Phase 
N/A
0
1
2
3
4


Please login to post a comment.

Comments

No comments yet.